A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 979-986

  Eura, Masao ^a   Chikamatsu, Kazuaki ^a   Katsura, Fumihiro ^a   Obata, Atsushi ^a   Sobao, Yuji ^a   Takiguchi, Masafumi ^a   Song, Yongsheng ^b   Appella, Ettore ^b   Whiteside, Theresa L ^c,d   DeLeo, Albert B ^c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 7; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR VACCINE;

ALLELE; AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE INDUCTION; HEAD CANCER; HUMAN; HUMAN CELL; NECK CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; BINDING, COMPETITIVE; CARCINOMA, SQUAMOUS CELL; CYTOTOXICITY, IMMUNOLOGIC; HEAD AND NECK NEOPLASMS; HLA-A ANTIGENS; HUMANS; K562 CELLS; MUTATION; OLIGOPEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12944265535     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boon, T., and van der Bruggen, P. Human tumor antigens recognized by T lymphocytes. J. Exp. Med., 183: 725-729, 1996.
2. Robbins, P. F., and Kawakami, Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol., 8: 628-636, 1996.
3. Disis, M. L., and Cheever, M. A. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol., 8: 637-642, 1996.
4. Bohm, C. M., Hanski, M-L., Stefanovic, S., Rammensee, H-G., Stein, H., Taylor-Papadimitriou, J., Riecken, E-T., and Hanski, C. Identification of HLA-A2-restricted epitopes of the tumor-associated antigen MUC2 recognized by human cytotoxic T cells. Int. J. Cancer, 75: 688-693, 1998.
5. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
6. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate specific antigen. J. Natl. Cancer Inst., 89: 293-300, 1997.
7. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
8. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
9. Liloglou, T., Scholes, A. G. M., Spandidos, D. A., Vaughan, E. D., Jones, A. S., and Field, J. K. p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Res., 57: 4070-4074, 1997.
10. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
11. DeLeo, A. B. p53-based immunotherapy of cancer. Crit. Rev. Immunol., 18: 29-35, 1998.
12. Mayordomo, J. I., Zorina, T., Storkus, W. J., Celluzzi, C., Falo, L., Melief, C. J., Ildstad, S. T., Kast, W. M., DeLeo, A. B., and Lotze, M. T. Bone-marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nat. Med., 1: 1298-1302, 1995.
13. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., and DeLeo, A. B. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357-1365, 1996.
14. Vierboom, M. P. M., Nijiman, H. W., Offringa, R., van der Voort, E. I. H., van Hall, T., van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., and Melief, C. J. M. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695-704, 1997.
15. Nijiman, H. W., Houbiers, J. G. A., van der Burg, S. H., Vierboorn, M. P. M., Kenemans, P., Kast, W. M., and Melief, C. J. M. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsivsness to peptides. J. Immunother., 14: 121-126, 1993.
16. Houbiers, J. G. A., Nijiman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J. H., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. M. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
17. Nijiman, H. W., van der Burg, S. H., Vierboom, H. P. M., Houbiers, J. G. A., Kast, W. M., and Melief, C. J. M. p53, a potential target for tumor-directed T cells. Immunol. Lett., 40: 171-178, 1994.
18. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA., 92: 11993-11997, 1995.
19. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Sveigaard, A., van der Burg, S., Nijiman, H. W., Melief, C. J., and Claesson, H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
20. Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., and Sherman, L. A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med., 185: 833-841, 1997.
21. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J-G., and Choppin, J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol., 160: 328-333, 1998.
22. MaCarty, T. M., Liu, X., Sun, J-Y., Peralta, E. A., Diamond, D. J., and Ellenhorn, D. I. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res., 58: 2601-2605, 1998.
23. Chikamatsu, K., Nakano, K., Storkus, W. J., Appella, E., Lotze, M. T., Whiteside, T. L., and DeLeo, A. B. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin. Cancer Res., 5: 1281-1288, 1999.
24. Imanishi, T., Akaza, T., Kimura, A., Tokunaga, K., and Gojobori, T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K. Tsuji, M. Aizawa, and T. Sasazuki (eds.), Human Leukocyte Antigens 1991: Proceedings of the Eleventh International Histocompatibility Workshop and Conference, Vol. 1, pp. 1066-1077. Tokyo: Oxford University Press, 1992.
25. Fukiage, T., Chikamatsu, K., Matsuoka, M., Murakami, H., Eura, M., Masuyama, K., and Ishikawa, T. Establishment of a human cell line from maxillary squamous cell carcinoma and its biological features as a stimulator for induction of cytotoxic T lymphocytes. Auris Nasus Larynx, 21: 163-172, 1994.
26. Date, Y., Kimura, H., Kato, H., and Sasazuki, T. DNA typing of the HLA-A gene: population study and identification of four new alleles in Japanese. Tissue Antigens, 47: 93-101, 1996.
27. Obata, A., Eura, M., Sasaki, J-I., Saya, H., Chikamatsu, K., Tada, M., Iggo, R., and Yumoto, E. Clinical significance of p53 functional loss in squamous cell carcinoma of the oropharynx. Int. J. Cancer, in press, 2000.
28. Ibe, M., Ikeda Moore, Y., Miwa, K., Kaneko, K., Yokota, S., and Takiguchi, M. Role of strong anchor residues in the effective binding of 10-mer and 11-mer peptides to HLA-A*2402 molecules. Immunogenetics, 44: 233-241, 1996.
29. Sakaguchi, T., Ibe, M., Miwa, K., Kaneko, Y., Yokota, S., Tanaka, K., and Takiguchi, M. Binding of 8-mer to 11-mer peptides carrying the anchor residues to slow assembling HLA class I molecules (HLA-B*5101). Immunogenetics, 45: 250-265, 1997.
30. Sallusto, F., and Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin-4 and down regulated by tumor necrosis factor-α. J. Exp. Med., 179: 1109-1118, 1994.
31. Oiso, M., Eura, M., Takiguchi, M., Sobao, Y., Masuyama, K., Nakashima, M., Itoh, K., and Ishikawa, T. A newly identified MAGE-3-derived epitope recognized by HLA-A24 restricted cytotoxic T lymphocytes. Int. J. Cancer, 81: 387-394, 1999.
32. Kubo, R. T., Sette, A., Grey, H. M., Appella, E., Sakaguchi, K., Zhu, N-Z., Arnott, D., Sherman, N., Shabanowitz, J., Michel, H., Bodnar, W. M., Davis, T. A., and Hunt, D. F. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol., 152: 3913-3924, 1994.
33. Lehner, P. J., and Cresswell, P. Proccessing and delivery of peptides presented by MHC class I molecules. Curr. Opin. Immunol., 8: 59-67, 1996.
34. Groettrup, M., Soza, A., Kuckelkorn, U., and Kloetzel, P-M. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol. Today, 17: 429-435, 1996.
35. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res., 56: 2649-2654, 1996.
36. Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P-M., and Sherman, L. A. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med., 188: 1017-1028, 1998.
37. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol., 28: 305-316, 1998.